George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Why such a drop
I lost patience with GSK years ago. The present CEO may not come highly recommended,but sadly the best in the last 25 years. Some totally inept people have run this outfit for decades. If you doubt me, look up the sp back in 2000 and 2001.
I am losing my patience with GSK. The split has done nothing for holders. Something needs to change quick here starting with the CEO getting the axe.
It weird I notice that too. When market go down this and halon goes up? True defense stock?
1358p as I type - I wonder if the fact that the Dollar has now peaked and Sterling now moving up as a consequence this is having a negative affect on the likes of GSK ?
Am I the only one that tired of the constant negative influence the USA has on GSK and other UK companies ..Whether its drug reviews , drug controls/bans , legal action by fire chasing US lawyers etc etc etc GSK is constantly on the back foot and being held back .I have never thought there ever was a special relationship with the USA ! its America first always in Pharma and any other industry UK companies are inolved in with the USA.Its about time the UK stands up to the USA , look at Covid , look at how BP got taken to the cleaners big time years ago and it s the same with the tabacco industry america first always they support the US industries we let ours flounder and get sued by no win no fee lawyers out for a fast Buck and our SP sufferes big time. . Have a good weekend everyone im off out .
Think the sp still has lots of legs so rather than waiting for a drop have added. :-).
Shaun, Many thanks for the info. :-).
It seems support is still there, and it's oversold on the 1hr RSI.
Bullish candle forming for today! Nuts I should have bough a lot more at 1377p!
https://www.tradingview.com/chart/GSK/noj6pcd6-GSK-The-line-of-support/
I see Blatter says awarding the World Cup to Qatar was a mistake, bet the Rolex in his goody bag wasn’t. Tw##.
I see. I thought that would be the case because it seems logical. But I thought it was worth getting confirmation.
The clinical trial precedes the full approval by regulators so a submission based on actual performance rather than what was 'hoped for' is still possible....it just means it will be approved with a different intended purpose....
The viagra comment is still valid....it was found in trials that it did not do what it was intended but had a rather useful side effect...
Thanks for replying.
I should have explained that I was asking about a specific drug and trial protocol. Its trial from last year make me think it should meet its secondary endpoints on an upcoming trial (lower mortality and less chance of needing mechanical ventilation) but it might struggle with the primary endpoint (time to recovery).
So I intended it as a technical question about the regulatory process, i.e. "Does missing the primary endpoint always guarantee it's refused approval even if it meets the the secondary endpoints and demonstrates it can save lives?".
It's Synairgen's antiviral drug SNG001 by the way, in case you're wondering.
There are lots of dependencies so there is no clearcut answer to a question like this.
The intended purpose of the drug could alter. Provided that the benefit of use outweigh the risks it could still be approved. The drug company may find that it cannot be marketed simply because the cost is prohibitive or a less costly alternative exists that means it will never find a market.....
Just remember Viagra started life as a drug to treat a heart condition.....it may not have been effective enough at that but it certainly brought a benefit...
Hi, I have a quick question for anyone with more experience in clinical drug development than I do:
If a drug misses its primary endpoint (time taken to recover) in a large, phase 3 trial but shows statistical significance at reducing mortality, is the failure to hit the primary endpoint likely to do much to reduce its chance of FDA approval?
Drifting, you seem to think GSK is my only share. As of this morning it makes up 4.4% of my portfolio. But thanks for the advice about broadening my horizons, doing some better research, diversifying and "going global" (have I missed anything?). I'll be sure to crack on with all of that straightaway.
Hello again Seaking1. OOverreaction as usual here. Not great news but wrong for some to blame Emma. I also note the recent strength in Haleon.
Ha,ha, I have supported Liverpool since 1964. Ups and. Downs. I’ve been. In gsk for about 5 years but I do think they have a good future now.and have been adding on drops now with no more selling. :-).
So many selling , More price drops are some observers considering when best time to add.
though i have proved my broker wrong on GSK back in 20008 by buying AZN! can’t believe my luck, bought 350 lol
Twonko, youv lost out big time, you need to broaden your horizon and look global.
Look at graphs abd do better research is my point.
You need to diversify and get out if UK stocks, they severely underperform global stocks like JNJ, BMY, NVS, ROCHE, VERT, ABBVIE, etc.
Gsk is just a cash cow which i have repeatedly said before. UK stocks need to reduce there payouts save money and invest better
Seaking I would agree with you but I've been saying the same for too many years and the future never seems to come for GSK. Side by side with any one of numerous other large pharmas, GSK comes a pitiful second. It's just like being a Spurs supporter, which I have been since 1965. A life dogged by despondency and under-achievement (them, not me).
"resign, the shares would gain 20% on that alone."
Maybe slightly unfair, but I picture Liz truss when I see Walmsley - an unshakeable belief in her own competence, in the face of thin expertise in the field and woeful performance and value destruction, appointed for God knows what reason (well one can speculate)! And doubtless glee in the markets if she were shown the door.
I love these dips to put a little more in and bring the average down.
Shareholder value destruction continues despite the split. She got what she wanted in a debt free enviroment and the relentless charge to zero is in full swing. God knows how she sleeps at night although maybe the reward package is helpful. Please do the decent thing and resign, the shares would gain 20% on that alone.